The content on this site is intended for healthcare professionals only
Dr O'Brien and Prof McVie discuss and answer questions about their presentations on the pros and cons of using PDL1 and other biomarkers for selecting patients for immune checkpoint therapies.
The potential of T-cell engagers in SCLC treatment
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Hormonal receptor positive breast cancer adjuvant and metastatic indications
